Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can targeted drug cocktails tame mesothelioma?

NCT ID NCT03654833

Disease control Sponsor: University of Leicester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial is testing several different targeted drug combinations in people with mesothelioma that has returned after initial treatment. The goal is to see which therapies can control the disease and potentially improve survival. Participants are assigned to a treatment based on the molecular profile of their tumor, aiming for a more personalized approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multiple targeted therapies: rucaparib, abemaciclib, pembrolizumab with bemcentinib, atezolizumab with bevacizumab, and dostarlimab with niraparib
What this could lead to
If successful, this trial could identify which targeted therapy works best for specific mesothelioma subtypes, leading to more personalized and effective treatment options.
What could go wrong
This is an early-phase trial, so the drugs may not work as hoped or may cause significant side effects. Results may not apply to all mesothelioma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

186 people

The number who actually took part.

Started

Jan 2019

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA FOR PRE-SCREENING * Histologically confirmed MM with an available biopsy for research purposes * Male or female patients aged ≥18 years. * Expected survival of ≥12 weeks or greater * ECOG PS 0-1 * CT scan chest, abdomen (and pelvis if applicable) confirming disease progression. * Patients must have received at least one prior line of therapy to include a platinum doublet first-line chemotherapy (within or outside of another clinical trial) * Willing to consent for molecular screening of archived tumour block (PIS1 \& CF1) EXCLUSION CRITERIA FOR PRE-SCREENING * Patients with a diagnosis of a second malignancy except prostate or cervical cancer in remission, patients with a diagnosis of basal cell carcinoma of the skin or superficial bladder cancer. * Uncontrolled CNS disease. Asymptomatic brain metastases are allowed if previously treated with radiotherapy \>28 days prior to starting the investigational agent. * New York Heart Association Class II or greater congestive heart failure. * Patients with severe hepatic insufficiency or severe renal impairment. * Patients requiring long term oxygen therapy. * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. Each individual MiST drug protocol contains the eligibility criteria specific to the treatment allocated to the patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mesothelioma, malignant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mesothelioma, malignant

Contacts and locations

Locations

  • University Hospitals of Leicester NHS Trust

    Leicester, LE1 5WW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.